Ibuprofen 200mg / Codeine 12.8mg tablets

IntroductionVenous ulceration (VU) is a chronic lower limb wound caused by sustained venous hypertension. Treatment includes compression therapy, wound care and surgical intervention. Due to the prolonged nature of wound healing, patients experience a substantial burden on quality of life, largely influenced by pain. Existing literature generalises findings across all chronic wounds and there are no published reviews or specific guidelines informing pharmacological pain management for patients with VU.MethodsFive databases were searched to identify studies evaluating the effectiveness of pharmacological interventions for VU pain, published in English between 2000 and 2024. The CASP appraisal tools were used to assess the quality of publications, and findings are reporting descriptively and following PRISMA guidance.ResultsInitial literature searches yielded 1,161 references, of which 447 were duplicates. Once screening was complete, thirteen studies were included in this evaluation. The majority (10/13) were randomised controlled trials comparing pharmacological interventions with standard care. Small sample sizes and poor reporting quality were common across all papers, and overall limits the evidence. Eight studies evaluated ibuprofen-impregnated dressings, all reporting some degree of pain reduction. Three studies investigated localized oxygen therapy, demonstrating improved wound healing outcomes. However, pain reduction was not statistically significant and may be secondary to healing. The remaining two studies examined topical sevoflurane and aspirin. Sevoflurane showed pain reduction over time in a single, low-quality retrospective study. The aspirin trial was inconclusive due to poor recruitment and underpowering.ConclusionCurrently, there is a lack of high-quality studies, evaluating the pharmacological treatment of pain in people experiencing VU. While there may be some evidence to support the use of topical agents such as ibuprofen, further industry-independent efficacy studies and cost analyses are required. Further research is also required to compare standard of care to commonly used agents such as oral paracetamol.

Abstract licence: CC BY-NC

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a well-known cause of systemic hypersensitivity (urticaria, angioedema, and bronchospasm). Ocular involvement is usually described as merely a component of a systemic reaction. It should be distinguished from the local toxicity of topical ocular NSAIDs. To our knowledge, very few cases of isolated allergic conjunctivitis induced by oral NSAIDs have been reported. We report the case of a 24-year-old woman with no history of atopy, who had presented for the past 7 months with recurrent bilateral asymmetric allergic conjunctivitis, predominantly affecting the right eye and strictly coinciding with her menstrual cycle. Examination revealed reduced visual acuity due to conjunctival chemosis and tearing, at 20/25 (LogMAR 0.10) in the right eye and 20/22 (LogMAR 0.05) in the left eye. Allergy testing, including prick tests and eosinophil counts, did not identify a relevant causative allergen explaining the clinical presentation. A detailed medication history revealed a temporal correlation with oral ibuprofen used for severe dysmenorrhea, without any accompanying cutaneous, respiratory, or systemic symptoms. Upon discontinuation of ibuprofen and its replacement with paracetamol and codeine, no recurrence was observed for four consecutive months, and an oral provocation test performed in the fifth month was positive, with mild conjunctivitis confirming the diagnosis. We report a case of isolated allergic conjunctivitis induced by oral NSAIDs and confirmed by an oral provocation test, which highlights the importance of a systematic review of medication history in all cases of recurrent conjunctivitis and that oral NSAIDs should be considered in the diagnosis of recurrent conjunctivitis.

Abstract licence: CC BY

ObjectiveTo systematically evaluate the comparative efficacy and safety of common pharmacological strategies for managing post-photorefractive keratectomy (PRK) eye pain through a network meta-analysis, providing evidence-based guidance for clinical medication.MethodsRandomized controlled trials (RCTs) were systematically retrieved from Cochrane Library, Web of Science, PubMed, and EMbase (from inception to November 15, 2025). Using R Studio, we conducted a network meta-analysis to assess differences in Visual Analogue Scale (VAS) scores and adverse events across pharmacological interventions. SUCRA (Surface Under the Cumulative Ranking) values were calculated to determine the relative ranking of interventions, while accounting for heterogeneities in administration timing and dosage.ResultsA total of 28 studies were included, involving 2,797 patients. In route-stratified analyses, Ofloxacin (SUCRA = 0.84) and Proparacaine (0.76) were the top-ranked topical agents for analgesia, while Codeine combined with Acetaminophen (0.71) ranked highest among systemic agents. The exploratory combined network yielded identical top-three rankings, though these cross-route comparisons are susceptible to transitivity violations. Notably, effect sizes for most interventions relative to placebo spanned the line of no effect. Regarding safety, Diclofenac (SUCRA = 0.81), Ketorolac (0.70), and Nepafenac (0.53) demonstrated the optimal profiles. The highest numbers of adverse events occurred with Pregabalin (39 cases), Fentanyl (20 cases), and Codeine combined with Acetaminophen (13 cases); however, safety conclusions remain limited as only seven studies reported highly heterogeneous adverse event data.ConclusionOfloxacin demonstrates superior relative efficacy for pain control following PRK, while Diclofenac offers the most favorable safety profile. Clinicians should synthesize these comparative findings with individual patient profiles to optimize drug selection, ensuring a balanced approach between effective pain relief and minimized adverse risks.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420251238092, CRD420251238092.

Abstract licence: CC BY